The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Increase In Market Value Is Predicted For The Post-Operative Nausea And Vomiting Market During The 2026–2030 Period?
The market size for post-operative nausea and vomiting has experienced substantial growth in recent years. It is projected to expand from $2.25 billion in 2025 to $2.41 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.0%. This historical growth can be linked to several contributing factors, including an increase in surgical procedure volumes, the broader application of general anesthesia, the availability of serotonin antagonist drugs, the expansion of hospital surgical infrastructure, and improved post-operative care guidelines.
The market for post-operative nausea and vomiting (PONV) is anticipated to experience robust expansion over the coming years. This market is projected to reach $3.13 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.7%. The expansion during this outlook period is driven by factors such as an increasing need for individualized anesthesia care, the greater implementation of preventive antiemetic treatments, the proliferation of ambulatory surgical centers, a heightened emphasis on metrics related to patient satisfaction, and rising investments in innovations within perioperative care. Key developments expected during the forecast period encompass a broader embrace of multimodal PONV management approaches, an increase in the utilization of combined antiemetic therapies, a stronger concentration on risk-stratified treatment plans, the wider availability of non-pharmacological interventions, and an amplified focus on enhancing patient comfort and recovery.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=22109&type=smp
What Are The Main Drivers Accelerating The Growth Of The Post-Operative Nausea And Vomiting Market?
The increasing number of surgical procedures is anticipated to fuel the expansion of the Post-Operative Nausea And Vomiting Market in the future. These medical interventions involve the use of tools to identify, treat, or remove damaged tissues, organs, or abnormalities through cutting or manipulation. The rise in surgical procedures is attributed to advancements in medical technology, making surgeries safer, more effective, and minimally invasive, thus increasing patient acceptance and broader applicability. Effective management of post-operative nausea and vomiting improves surgical procedures by enhancing patient comfort, shortening recovery times, minimizing complication risks, ensuring smoother post-operative care, and ultimately bettering overall surgical outcomes. For instance, in November 2024, data from the Australian Institute of Health and Welfare, an Australia-based government agency, indicated that during the 2023–24 period, 771,600 patients were admitted for surgery from public hospital elective surgery waiting lists, representing a 4.9% increase compared to 2022–23. Consequently, the growing volume of surgical procedures is propelling the growth of the Post-Operative Nausea And Vomiting Market. The expansion of healthcare infrastructure is projected to drive the future growth of the Post-Operative Nausea And Vomiting Market. Healthcare infrastructure comprises the physical facilities, equipment, and organizational frameworks that support healthcare service delivery, including hospitals, surgical centers, and medical technologies. This infrastructural growth is primarily fueled by increasing patient populations and heightened demand for surgical procedures, as an aging demographic and widespread chronic diseases necessitate greater hospital capacity and surgical interventions. The establishment of new hospitals and surgical facilities leads to a higher volume of performed surgical procedures, which directly increases the likelihood of postoperative complications requiring antiemetic management and treatment solutions. For example, in May 2023, according to the American Health Care Association, a US-based nonprofit organization, the United States contained 6,129 hospitals, marking a 0.591% increase from the previous year when there were 6,093 hospitals. Therefore, the expanding healthcare infrastructure is a significant factor driving the growth of the Post-Operative Nausea And Vomiting Market.
Which Segment-Based Categories Are Covered In The Post-Operative Nausea And Vomiting Market?
The post-operative nausea and vomiting market covered in this report is segmented –
1) By Treatment Type: Serotonin Antagonists, Steroids, Dopamine Antagonists, Neurokinin NK-1 Receptor Antagonists, Non-pharmacological Treatment, Other Treatment Types
2) By Route Of Administration: Oral, Intravenous, Transdermal, Other Route Of Administrations
3) By Patient Demographics: Pediatric Patients, Adult Patients, Geriatric Patients
4) By Surgical Procedure Type: Orthopedic Surgery, Gynecological Surgery, General Surgery, Cardiac Surgery, Ophthalmic Surgery
5) By End-User: Hospitals, Ambulatory Surgical Centers, Specialty Clinics, Other End-Users
Subsegments:
1) By Serotonin Antagonists Type: Ondansetron, Granisetron, Palonosetron, Dolasetron, Tropisetron
2) By Steroids Type: Dexamethasone, Methylprednisolone, Hydrocortisone, Prednisolone, Betamethasone
3) By Dopamine Antagonists Type: Metoclopramide, Droperidol, Prochlorperazine, Domperidone, Chlorpromazine
4) By Neurokinin NK-1 Receptor Antagonists Type: Aprepitant, Fosaprepitant, Rolapitant, Netupitant, Casopitant
5) By Non-Pharmacological Treatment Type: Acupressure, Aromatherapy, Hypnotherapy, Electroacupuncture, Ginger Supplements
6) By Other Treatment Types: Antihistamines, Anticholinergics, Cannabinoids, Combination Therapy, Herbal & Natural Remedies
Which Trends Are Guiding The Development Of The Post-Operative Nausea And Vomiting Market?
Major companies operating in the post-operative cataract surgery inflammation treatment market are focusing on developing innovative therapies, such as postoperative ocular analgesics, to enhance the relief of pain and inflammation following ocular surgery. Postoperative ocular analgesics refer to therapeutic agents specifically designed to alleviate pain and reduce inflammation in the eye after surgical procedures, thereby promoting patient comfort and supporting optimal recovery outcomes. For instance, in March 2024, Formosa Pharmaceuticals, a Taiwan-based pharmaceutical company in collaboration with AimMax Therapeutics, a US-based biotechnology company, received FDA approval for clobetasol propionate ophthalmic suspension 0.05% (APP13007) for the treatment of post-operative pain and inflammation following ocular surgery. APP13007 is the first ophthalmic clobetasol propionate product approved by the FDA and marks the introduction of the first new ophthalmic steroid on the market in over 15 years, offering a novel option to manage post-operative ocular inflammation and enhance patient recovery.
Which Industry Players Are Present In The Post-Operative Nausea And Vomiting Market?
Major companies operating in the post-operative nausea and vomiting market are Pfizer Inc., Merck KGaA, Novartis AG, GlaxoSmithKline Plc, Takeda Pharmaceutical Company Limited, Baxter Corporation, Teva Pharmaceutical Industries Ltd., Sandoz Group AG, Daiichi Sankyo Inc., Fresenius Kabi AG, Eisai Co. Ltd., Dr. Reddy’s Laboratories, Cipla Ltd., Alkem Laboratories Ltd., Eagle Pharmaceuticals Inc., Helsinn Healthcare SA, Heron Therapeutics Inc., Sun Pharmaceutical Industries Ltd., Johnson And Johnson, Sanofi, Aurobindo Pharma Ltd., Lupin Limited
Access The Complete Post-Operative Nausea And Vomiting Market Report:
Which Area Represents The Largest Portion Of The Post-Operative Nausea And Vomiting Market?
North America was the largest region in the post-operative nausea and vomiting market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the post-operative nausea and vomiting market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Post-Operative Nausea And Vomiting Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/customise?id=22109&type=smp
Browse Through More Reports Similar to the Global Post-Operative Nausea And Vomiting Market 2026, By The Business Research Company
Osteoporosis Treatment Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/osteoporosis-treatment-global-market-report
Osteoporosis Drugs Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/osteoporosis-drugs-global-market-report
Mineral And Bone Disorder Treatment Global Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model